{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:44Z","timestamp":1792898924407,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijantimicag.2018.11.023","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:30:42Z","timestamp":1544293842000},"page":"429-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B.","family":"Chastain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0001","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.idc.2017.01.010","article-title":"Osteomyelitis","volume":"31","author":"Schmitt","year":"2017","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 5","key":"10.1016\/j.ijantimicag.2018.11.023_bib0003","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1086\/533591","article-title":"Pathogenesis of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Gordon","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fcimb.2015.00085","article-title":"Staphylococcus aureus vs. osteoblast: relationship and consequences in osteomyelitis","volume":"5","author":"Josse","year":"2015","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0005","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0007","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.mcna.2013.03.010","article-title":"Osteomyelitis in the diabetic foot: diagnosis and management","volume":"97","author":"Game","year":"2013","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jcpt.12030","article-title":"The potential role of newer Gram-positive antibiotics in the setting of osteomyelitis of adults","volume":"38","author":"Moenster","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0009","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1957","article-title":"Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin","volume":"37","author":"Delaportas","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0012","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IPC.0000000000000599","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis with outpatient oritavancin therapy","volume":"26","author":"Ruggero","year":"2018","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8435257","article-title":"Patient characteristics and outcomes of outpatient parenteral antimicrobial therapy: a retrospective study","volume":"2016","author":"Yan","year":"2016","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1056\/NEJM197001222820406","article-title":"Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects","volume":"282","author":"Waldvogel","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-17","article-title":"Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions","volume":"31","author":"Kavanagh","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0016","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s13063-015-1098-y","article-title":"Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial","volume":"16","author":"Li","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0017","series-title":"27th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID); 22\u201325 April 2017","article-title":"The OVIVA trial: oral versus intravenous antibiotics in the management of bone and joint infection\u2014a multicentre open label randomised non-inferiority study","author":"Scarborough","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0018","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1128\/AAC.00981-15","article-title":"Oritavancin pharmacokinetics and bone penetration in rabbits","volume":"59","author":"Lehoux","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0019","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0020","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.05098-14","article-title":"Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide","volume":"59","author":"Jones","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0021","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0022","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The whole price of vancomycin: toxicities, troughs, and time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0023","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjmed.2008.01.046","article-title":"Multicenter evaluation of vancomycin dosing: emphasis on obesity","volume":"121","author":"Hall","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0024","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jac\/dkx452","article-title":"Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline","volume":"73","author":"Turner","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0026","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0027","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/00365548.2014.914241","article-title":"Prognostic factors of calcaneal osteomyelitis","volume":"46","author":"Merlet","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0028","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cpm.2010.04.003","article-title":"Management of calcaneal osteomyelitis","volume":"27","author":"Chen","year":"2010","journal-title":"Clin Podiatr Med Surg"},{"key":"10.1016\/j.ijantimicag.2018.11.023_bib0029","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.fcl.2014.06.012","article-title":"Osteomyelitis of the foot and ankle: diagnosis, epidemiology, and treatment","volume":"19","author":"Lindbloom","year":"2014","journal-title":"Foot Ankle Clin"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T06:37:11Z","timestamp":1565764631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0924857918303625"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.023","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}